Australia to prescribe MDMA and psilocybin for PTSD and depression in world first
Nature July 13, 2023 DOI: 10.1038/d41586-023-02093-8 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Peer reviewed |
|---|---|
| Topics | Depression MDMA Psilocybin PTSD |
| Keywords | Psychiatric disorders |
| Citations | 55 |
| Key points | The decision to make previously illicit drugs available was rushed. |
Abstract
Decision to make the previously illicit drugs available is dogged by suggestions that it was rushed. Decision to make the previously illicit drugs available is dogged by suggestions that it was rushed.
In the evidence
This study is part of the evidence base for 2 syntheses in the library. Here is how each one recorded it.
-
Reports that Australia's decision to prescribe MDMA and psilocybin for PTSD and depression was described as rushed.
Synthesized
-
Reports that Australia's decision to make MDMA and psilocybin available for PTSD and depression was dogged by suggestions that it was rushed.
Synthesized
Citations in the library
Cited by 51
- Extended difficulties following the use of psychedelic drugs: A mixed methods study PLoS One October 24, 2023
- Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases Cochrane Database of Systematic Reviews September 11, 2024
- Psilocybin for the treatment of Alzheimer’s disease Frontiers in Neuroscience July 10, 2024
- Mitochondrial Metabolism in Major Depressive Disorder: From Early Diagnosis to Emerging Treatment Options. Journal of Clinical Medicine March 17, 2024
- Personal psychedelic experience of psychedelic therapists during training: should it be required, optional, or prohibited? International Review of Psychiatry June 12, 2024
and 46 more in the library
Cites 4
- Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine November 3, 2022
- MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine June 1, 2021
- The Psychedelic Renaissance in Clinical Research: A Bibliometric Analysis of Three Decades of Human Studies with Psychedelics. Journal of Psychoactive Drugs 2023
- Why didn’t the TGA consult with Australian researchers and clinicians with experience in psilocybin-assisted psychotherapy for treatment-resistant major depressive disorder? Australian & New Zealand Journal of Psychiatry May 3, 2023